Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1645 1652 1758 1759 1767 1777 1796 1797
This examiner grants 46% of resolved cases
Rebecca M. Fritchman examines cases in Tech Center 1700 and Art Unit 1645, with 663 resolved cases. The allowance rate is 45.7%, and the median days to allowance is 1470. This indicates a specific prosecution environment. The 663 resolved cases provide a stable baseline for these metrics.
The interview lift is 35.3%, which is a significant positive factor. This 35.3% lift is high relative to the 45.7% allowance rate. Despite the 1470-day median pendency, an interview can dramatically improve the odds of success. Practitioners should prioritize interviews as a primary strategy. The 35.3% lift and 45.7% allowance rate are the key data points for applicants. Success typically follows the 1470-day median path in this art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19462819 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | Final Rejection | Quest Diagnostics Investments Incorporated |
| 18147094 | USE OF BIOMARKERS TO DETERMINE SUB-ACUTE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY (CT) SCAN THAT IS NEGATIVE FOR A TBI OR NO HEAD CT SCAN | Non-Final OA | Abbott Laboratories |
| 18604429 | METABOLOMIC ANALYSIS | Non-Final OA | Genentech, Inc. |
| 17423868 | Urine metabolomics based method of detecting renal allograft injury | Non-Final OA | The Regents of the University of California |
| 17633917 | BIOMARKERS FOR NEURODEGENERATIVE DISORDERS | Non-Final OA | The Johns Hopkins University |
| 17435471 | HEMOLYSIS DETECTION BLOOD TESTING DEVICE | Non-Final OA | Siemens Healthcare Diagnostics Inc. |
| 17842433 | CSF-BASED PROGNOSTIC BIOMARKERS IN ALZHEIMER'S DISEASE AND METHODS OF USE THEREOF | Final Rejection | Emory University |
| 17787015 | ENDOTOXIN DETECTION | Final Rejection | Eli Lilly and Company |
| 18696187 | METHOD FOR DETECTING AND/OR QUANTIFYING MOOD DISORDER AND/OR IMPROVEMENTS OF THE MOOD DISORDER STATUS USING TRIGONELLINE AS BIOMARKER AND IMPROVED METHODS AND COMPOSITIONS THEREOF | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18559869 | METHOD FOR DETERMINING PERSONALIZED OMEGA-3 DOSE | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18718434 | METHOD FOR QUANTIFYING CARBON IN CARBIDES | Non-Final OA | JFE STEEL CORPORATION |
| 18606302 | Proteomic Risk Score For Osteoarthritis (OA) | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18221934 | ISOELECTRIC FOCUSING-BASED ENRICHMENT OF CHARGE VARIANT SPECIES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18286403 | Sample Conveying Device, Sample Analysis System, and Sample Pretreatment System | Final Rejection | Hitachi High-Tech Corporation |
| 17880676 | TARGET MATERIAL IDENTIFICATION METHOD | Final Rejection | Taiwan Semiconductor Manufacturing Company, Ltd. |
| 18028235 | CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION | Final Rejection | Roche Diagnostics Operations, Inc. |
| 19187629 | BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS | Non-Final OA | MOONLAKE IMMUNOTHERAPEUTICS AG |
| 18027393 | CONTINUOUS OPTICAL APTAMER SENSORS | Final Rejection | University Of Cincinnati |
| 17436218 | IN VIVO REVERSIBILITY OF HIGH MOLECULAR WEIGHT SPECIES | Non-Final OA | AMGEN INC. |
| 18014901 | GUIDING BLOOD PRODUCT ADMINISTRATION TO MITIGATE BLEEDING RISK | Non-Final OA | CHILDREN'S MEDICAL CENTER CORPORATION |
| 16978959 | DETECTION OF ALZHEIMER'S DISEASE (AD), FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AMYOTROPHIC LATERAL SCHLEROSIS (ALS), PARKINSON'S DISEASE (PD), AND DEMENTIA WITH LEWY BODIES (DLB) INDICATED BY PHOSPHORYLATION OF MARCKS | Final Rejection | DENKA COMPANY LIMITED |
| 18639371 | ALKENE DETECTION OF OZONE | Non-Final OA | Hach Company |
| 16766956 | DETECTION OF BIOMARKERS | Non-Final OA | Imperial College of Science, Technology and Medicine |
| 18599007 | METHODS AND SYSTEMS FOR ESTIMATING AN AMOUNT OF A SEQUESTERED CARBON CONSTITUENT IN TOP AND SUB SOIL | Non-Final OA | QuantumPro, Inc. |
| 18689552 | SOLUTION FOR THE PRESERVATION OF CELLS | Non-Final OA | ANACYTE LABORATORIES GMBH |
| 18021229 | METHOD FOR DIAGNOSING ACTING OF NERVONIC ACID AND USE THEREOF | Non-Final OA | BAO FENG BIOTECH (BEIJING) CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy